Clear Cell Renal Cell Carcinoma

P2, N=62, Active, not recruiting, University of Southern California | Trial primary completion date: Dec 2025 --> Jun 2026

The LAC-TME classifier, integrating metabolic and immune data, offers a new tool for ccRCC prognosis and treatment guidance. Further validation is needed to confirm its clinical potential, reflecting the ongoing need for robust medical research.

NNMT is a promising prognostic biomarker and potential therapeutic target in ccRCC, supported by transcriptomic, clinical, and functional validation. While the prognostic relevance of HILPDA remains inconclusive, its metabolic associations suggest potential biological significance. Further studies with larger cohorts and in vivo validation are warranted.

P1/2, N=240, Recruiting, Regeneron Pharmaceuticals | N=150 --> 240

Both in vitro and in vivo experiments demonstrated that a low branched-chain amino acids (BCAAs) diet or treatment with the de-methylmalonylation agent MC3138 effectively inhibited M2 polarization of macrophages and tumor progression. These findings emphasize the critical role of MMA in ccRCC pathogenesis and suggest that combining a low-BCAAs diet with MC3138 therapy may offer a promising treatment strategy for ccRCC patients with elevated MMA levels.

These effects are mediated through the NRP2/NF-κB/TNFα axis, which also underlies NRP2-induced sorafenib resistance. Targeting this axis with the TNF-α inhibitor adalimumab effectively reversed sorafenib resistance in ccRCC, suggesting a promising therapeutic strategy.

Despite lower gene and UMI counts, snFlex reliably identified fine-grained states within CD8 + T cells, tumor-associated macrophages, and tumor compartments, comparable to those detected by scRNA-seq. Together, these findings highlight the distinct advantages of each technology depending on sample preservation type and study design, providing practical guidance for single-cell RNA profiling technology selection in translational studies using human tumor biopsies.

This study developed a TOP2A based index clinical model that will aid in predicting the prognosis of KIRC patients.

P2, N=36, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

P2, N=75, Suspended, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Suspended

Cell experiments revealed that interference of UBE2Q1-AS1 significantly inhibited the proliferation and migration of 786-O cells. The migrasome-associated lncRNA model accurately predicts ccRCC patient prognosis, offering new insights for immunotherapy and clinical applications.

CD70 is a viable biomarker for ccRCC lung metastases. CD70-targeted [18F]RCCB6 immuno-PET/CT accurately detects ccRCC lung metastases and other distant metastases.